HK1212694A1 - 四氫吡咯並三嗪類化合物 - Google Patents

四氫吡咯並三嗪類化合物

Info

Publication number
HK1212694A1
HK1212694A1 HK16100629.1A HK16100629A HK1212694A1 HK 1212694 A1 HK1212694 A1 HK 1212694A1 HK 16100629 A HK16100629 A HK 16100629A HK 1212694 A1 HK1212694 A1 HK 1212694A1
Authority
HK
Hong Kong
Prior art keywords
tetrahydropyrrolothiazine
compounds
tetrahydropyrrolothiazine compounds
Prior art date
Application number
HK16100629.1A
Other languages
English (en)
Inventor
Steven James Green
Dustin James Mergott
Brian Morgan Watson
Jr Leonard Larry Winneroski
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of HK1212694A1 publication Critical patent/HK1212694A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HK16100629.1A 2013-03-12 2016-01-21 四氫吡咯並三嗪類化合物 HK1212694A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361776819P 2013-03-12 2013-03-12
PCT/US2014/020070 WO2014143579A1 (en) 2013-03-12 2014-03-04 Tetrahydropyrrolothiazine compounds

Publications (1)

Publication Number Publication Date
HK1212694A1 true HK1212694A1 (zh) 2016-06-17

Family

ID=50382615

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16100629.1A HK1212694A1 (zh) 2013-03-12 2016-01-21 四氫吡咯並三嗪類化合物

Country Status (38)

Country Link
US (3) US8841293B1 (zh)
EP (1) EP2970336B1 (zh)
JP (1) JP6095844B2 (zh)
KR (1) KR101688761B1 (zh)
CN (1) CN105026404B (zh)
AP (1) AP2015008713A0 (zh)
AR (1) AR094918A1 (zh)
BR (1) BR112015018738A8 (zh)
CA (1) CA2898500C (zh)
CL (1) CL2015002529A1 (zh)
CR (1) CR20150418A (zh)
CY (1) CY1119585T1 (zh)
DK (1) DK2970336T3 (zh)
EA (1) EA026006B1 (zh)
ES (1) ES2653421T3 (zh)
HK (1) HK1212694A1 (zh)
HR (1) HRP20171851T1 (zh)
HU (1) HUE037487T2 (zh)
IL (1) IL240903B (zh)
JO (1) JO3317B1 (zh)
LT (1) LT2970336T (zh)
MA (1) MA38390B1 (zh)
ME (1) ME02910B (zh)
MX (1) MX2015012628A (zh)
MY (1) MY180083A (zh)
NO (1) NO3039297T3 (zh)
NZ (1) NZ712207A (zh)
PE (1) PE20151542A1 (zh)
PH (1) PH12015502031B1 (zh)
PL (1) PL2970336T3 (zh)
PT (1) PT2970336T (zh)
RS (1) RS56645B1 (zh)
SG (1) SG11201507499XA (zh)
SI (1) SI2970336T1 (zh)
TN (1) TN2015000340A1 (zh)
TW (1) TWI593692B (zh)
UA (1) UA112941C2 (zh)
WO (1) WO2014143579A1 (zh)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104364239B (zh) 2012-06-13 2017-08-25 霍夫曼-拉罗奇有限公司 二氮杂螺环烷烃和氮杂螺环烷烃
IN2015DN00960A (zh) 2012-09-25 2015-06-12 Hoffmann La Roche
PL2912041T3 (pl) 2012-10-26 2017-06-30 Eli Lilly And Company Pochodne tetrahydropirolotiazyny stanowiące inhibitory BACE
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
PE20160845A1 (es) 2013-11-26 2016-09-10 Hoffmann La Roche Nuevo octahidro-ciclobuta[1,2-c;3,4-c']dipirrol-2-ilo
TWI684452B (zh) 2014-03-14 2020-02-11 美國禮來大藥廠 胺基噻嗪化合物
MX2016010675A (es) 2014-03-26 2016-11-10 Hoffmann La Roche Compuestos condensados de [1,4]diazepina como inhibidores de produccion de la autotaxina (atx) y acido lisofosfatidico (lpa).
WO2015144605A1 (en) 2014-03-26 2015-10-01 F. Hoffmann-La Roche Ag Bicyclic compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors
TWI570127B (zh) * 2014-09-15 2017-02-11 美國禮來大藥廠 結晶型N-[3-[(4aR,7aS)-2-胺基-6-(5-氟嘧啶-2-基)-4,4a,5,7-四氫吡咯并[3,4-d][1,3]噻嗪-7a-基]-4-氟-苯基]-5-甲氧基-吡嗪-2-甲醯胺、其用途及醫藥組合物
TWI599358B (zh) 2014-09-16 2017-09-21 美國禮來大藥廠 組合療法
TWI574969B (zh) * 2015-01-30 2017-03-21 美國禮來大藥廠 甲苯磺酸鹽
AR103680A1 (es) 2015-02-23 2017-05-24 Lilly Co Eli Inhibidores selectivos de bace1
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
AR104241A1 (es) 2015-04-29 2017-07-05 Lilly Co Eli Derivados de tetrahidrofuro tiazina como inhibidores de bace1 selectivos
PE20180479A1 (es) 2015-09-04 2018-03-07 Hoffmann La Roche Nuevos derivados de fenoximetilo
AU2016328365B2 (en) 2015-09-24 2020-04-23 F. Hoffmann-La Roche Ag New bicyclic compounds as dual ATX/CA inhibitors
RU2724899C2 (ru) 2015-09-24 2020-06-26 Ф. Хоффманн-Ля Рош Аг Новые бициклические соединения в качестве дуальных ингибиторов atx/ca
MA42919A (fr) 2015-09-24 2018-08-01 Hoffmann La Roche Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
RU2018114289A (ru) 2015-09-24 2019-10-24 Ф. Хоффманн-Ля Рош Аг Бициклические соединения в качестве ингибиторов аутотаксина (atx)
TW201740954A (zh) * 2016-03-16 2017-12-01 美國禮來大藥廠 組合療法
TWI798751B (zh) 2016-07-01 2023-04-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
MA52722A (fr) 2016-12-15 2021-04-14 Amgen Inc Dérivés d'oxazine en tant qu'inhibiteurs de bêta-sécrétase et procédés d'utilisation
US11548903B2 (en) 2016-12-15 2023-01-10 Amgen Inc. Bicyclic thiazine and oxazine derivatives as beta-secretase inhibitors and methods of use
JP7159161B2 (ja) 2016-12-15 2022-10-24 アムジエン・インコーポレーテツド β－セクレターゼ阻害剤としてのシクロプロピル縮合チアジン誘導体および使用方法
EP3555084B1 (en) 2016-12-15 2022-03-16 Amgen Inc. Thiazine derivatives as beta-secretase inhibitors and methods of use
EP3555086B1 (en) 2016-12-15 2021-09-01 Amgen Inc. 1,4-thiazine dioxide and 1,2,4-thiadiazine dioxide derivatives as beta-secretase inhibitors and methods of use
WO2018167113A1 (en) 2017-03-16 2018-09-20 F. Hoffmann-La Roche Ag New bicyclic compounds as atx inhibitors
CN110392679B (zh) 2017-03-16 2023-04-07 豪夫迈·罗氏有限公司 可用作双重atx/ca抑制剂的杂环化合物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284957A (en) * 1992-09-03 1994-02-08 Eli Lilly And Company Excitatory amino acid receptor antagonists
WO2003082856A1 (en) * 2002-03-22 2003-10-09 Eli Lilly And Company Isoquinoline-3-carboxylic acid derivatives as excitatory amino acid receptor antagonists
AR054617A1 (es) 2005-06-14 2007-07-04 Schering Corp Derivados de pirrol[3, 4 - d]pirimidina como inhibidores de aspartil proteasas y composiciones farmacéuticas que los comprenden
US8173642B2 (en) 2005-10-25 2012-05-08 Shionogi & Co., Ltd. Aminodihydrothiazine derivatives
US8653067B2 (en) 2007-04-24 2014-02-18 Shionogi & Co., Ltd. Pharmaceutical composition for treating Alzheimer's disease
WO2009091016A1 (ja) * 2008-01-18 2009-07-23 Eisai R & D Management Co., Ltd. 縮合アミノジヒドロチアジン誘導体
TW201004957A (en) 2008-04-22 2010-02-01 Schering Corp Phenyl-substituted 2-imino-3-methyl pyrrolo pyrimidinone compounds as bace-1 inhibitors, compositions, and their use
TWI431004B (zh) * 2008-05-02 2014-03-21 Lilly Co Eli Ｂａｃｅ抑制劑
CA2727859C (en) 2008-06-13 2016-11-01 Shionogi & Co., Ltd. SULFUR-CONTAINING HETEROCYCLIC DERIVATIVE HAVING ß-SECRETASE-INHIBITING ACTIVITY
US8198269B2 (en) 2008-09-30 2012-06-12 Eisai R&D Management Co., Ltd. Fused aminodihydrothiazine derivative
AR077277A1 (es) 2009-07-09 2011-08-17 Lilly Co Eli Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer
JPWO2011071109A1 (ja) 2009-12-11 2013-04-22 塩野義製薬株式会社 アミノ基を有する縮合ヘテロ環化合物
GB201100181D0 (en) 2011-01-06 2011-02-23 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101139D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101140D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
EP2694521B1 (en) 2011-04-07 2015-11-25 Merck Sharp & Dohme Corp. Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
US8598161B2 (en) 2011-05-24 2013-12-03 Bristol-Myers Squibb Company Compounds for the reduction of beta-amyloid production
JO3143B1 (ar) * 2012-04-03 2017-09-20 Lilly Co Eli مركبات تتراهيدرو بيرولو ثيازين

Also Published As

Publication number Publication date
TW201520217A (zh) 2015-06-01
CA2898500A1 (en) 2014-09-18
EA201591491A1 (ru) 2016-01-29
WO2014143579A1 (en) 2014-09-18
MY180083A (en) 2020-11-20
PL2970336T3 (pl) 2018-03-30
US20140275044A1 (en) 2014-09-18
HUE037487T2 (hu) 2018-08-28
AR094918A1 (es) 2015-09-09
CN105026404B (zh) 2016-11-23
RS56645B1 (sr) 2018-03-30
IL240903A0 (en) 2015-10-29
SG11201507499XA (en) 2015-10-29
ME02910B (me) 2018-04-20
CR20150418A (es) 2015-09-16
SI2970336T1 (sl) 2017-11-30
JP6095844B2 (ja) 2017-03-15
CN105026404A (zh) 2015-11-04
LT2970336T (lt) 2018-01-10
US20150157641A1 (en) 2015-06-11
BR112015018738A8 (pt) 2018-01-23
ES2653421T3 (es) 2018-02-07
US8987254B2 (en) 2015-03-24
CA2898500C (en) 2017-11-14
EP2970336B1 (en) 2017-10-04
MA38390B1 (fr) 2020-01-31
EP2970336A1 (en) 2016-01-20
PE20151542A1 (es) 2015-10-28
CY1119585T1 (el) 2018-03-07
KR20150119070A (ko) 2015-10-23
EA026006B1 (ru) 2017-02-28
PT2970336T (pt) 2017-12-21
JO3317B1 (ar) 2019-03-13
PH12015502031A1 (en) 2016-01-18
UA112941C2 (uk) 2016-11-10
MA38390A1 (fr) 2018-08-31
US20140350245A1 (en) 2014-11-27
NO3039297T3 (zh) 2018-03-10
KR101688761B1 (ko) 2016-12-21
BR112015018738A2 (pt) 2017-07-18
HRP20171851T1 (hr) 2018-01-12
NZ712207A (en) 2019-09-27
DK2970336T3 (da) 2017-11-13
PH12015502031B1 (en) 2016-01-18
JP2016512252A (ja) 2016-04-25
TN2015000340A1 (en) 2017-01-03
IL240903B (en) 2018-12-31
CL2015002529A1 (es) 2016-03-28
MX2015012628A (es) 2016-07-07
AU2014228351A1 (en) 2015-09-17
AP2015008713A0 (en) 2015-09-30
US8841293B1 (en) 2014-09-23
TWI593692B (zh) 2017-08-01

Similar Documents

Publication Publication Date Title
HRP20171851T1 (hr) Spojevi tetrahidropirolotiazina
HK1222658A1 (zh) 氰基***化合物
GB201309085D0 (en) Compounds
GB201302927D0 (en) Compounds
GB201310542D0 (en) Compounds
GB201311951D0 (en) Compounds
GB201309508D0 (en) Compounds
GB201320636D0 (en) Compounds
GB201317619D0 (en) Compounds
GB201312901D0 (en) Compounds
GB201311953D0 (en) Compounds
EP3010923A4 (en) PYRROLOCHINAZOLINVERBINDUNGEN
EP2948457A4 (en) COMPOUNDS
GB201306794D0 (en) Compounds
GB201318461D0 (en) Compounds
GB201316014D0 (en) Compounds
GB201310460D0 (en) Compounds
GB201318323D0 (en) Compounds
GB201318143D0 (en) Compounds
GB201317118D0 (en) Compounds
GB201316717D0 (en) Compounds
GB201315947D0 (en) Compounds
GB201315253D0 (en) Compounds
GB201315254D0 (en) Compounds
GB201314700D0 (en) Compounds

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20220302